Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

RECOVERY (plasma), 2021
 
NCT04381936
RCTconvalescent plasma treatmentcontrolCOVID 19 hospitalizedNA
-/- inconclusive
    Balcells, 2020
     
    NCT04375098
    RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedlow
    28/30 inconclusive
    • inconclusive 33 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
    ConPlas-19, 2020
     
    NCT04345523
    RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
    38/43 inconclusive
      Gharbharan et al., 2020
       
      NCT04342182
      RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
      43/43 inconclusive
      • inconclusive 5 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
      Abolghasemi, 2020
       
      IRCT20200325046860N1
      OBSconvalescent plasma treatmentcontrolCOVID 19 hospitalizedcritical
      115/74 inconclusive

        COVID-19 mild to moderate meta-analysis

        Libster, 2020
         
        NCT04479163
        RCTconvalescent plasma treatmentplaceboCOVID-19 mild to moderatelow
        80/80 conclusif
        • demonstrated 48 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias
        PLACID, 2020
         
        CTRI/2020/04/024775
        RCTconvalescent plasma treatmentstandard of careCOVID-19 mild to moderatehigh
        235/229 suggested
        • inconclusive 7 % increase in death or transfer to ICU (PE) but with a low degree of certainty due to high risk of bias
        • suggested 20 % increase in PCR-negative conversion (7-day) but with a low degree of certainty due to high risk of bias

        COVID-19 severe or critically meta-analysis

        AlQahtani, 2020
         
        NCT04356534
        RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
        20/20 inconclusive
        • inconclusive 33 % decrease in ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
        Bajpai M, 2020
         
        NCT04346446
        RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallyhigh
        14/15 inconclusive
        • inconclusive 74 % decrease in off oxygenation (PE) but with a low degree of certainty due to high risk of bias
        PlasmAr, 2020
         
        NCT04344535
        RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallylow
        228/105 inconclusive
        • inconclusive 19 % decrease in clinical improvement (PE) with a high degree of certainty due to low risk of bias
        PlasmAr, 2020
         
        NCT04344535
        RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
        228/105 inconclusive
        • inconclusive 19 % decrease in clinical improvement (PE) with a high degree of certainty due to low risk of bias
        Li, 2015
         
        ChiCTR2000029757
        RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
        52/51 inconclusive
        • inconclusive 40 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
        Duan, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
        10/10 inconclusive
          Hegerova, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
          20/20 inconclusive
            Rasheed, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
            21/28 inconclusive
              Sean, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
              39/156 inconclusive
                Joyner, 2020
                 
                NCT04338360
                NRaconvalescent plasma treatmentconvalescent plasma treatmentCOVID-19 severe or criticallyserious
                515/561 inconclusive

                  PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                  Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).